Amsterdam, 2 - 3 March 2027
Schedule
Create your personal agenda –check the favourite icon
Mar 28:55
Conference pass
Chair's opening remarks
Keynotes
Mar 29:00
Conference pass
Implications of policy changes on market access
Keynotes
Christoph Glaetzer, Chief Global Value and Access Officer, Johnson & Johnson Innovative Medicine
Mar 29:40
Conference pass
Keynote panel: The future of European JCA: From Joint Assessments to National Access
Keynotes
Focus:HTA alignment, pricing and reimbursement impact, regulatory mechanics, and what "market readiness" really means under the EU HTA Regulation.
- What do the first assessments reveal about evidence requirements, timelines, and the operational bottlenecks HTA bodies are facing on the ground?
- How are unified European clinical assessmentstranslatinginto pricing, reimbursement, and economic decision-making at Member State level?
- Where can - and can't - Member States realistically align their processes? What national differences are proving durable, and why?
- Building a predictable pathway-What changes to the JCA framework would give developers greater certainty, while still acceleratingequitablepatient access across Europe?
Anne Willemsen, Chair JCA Subgroup, Zorginstituut Nederland
Fabienne Bartoli, Inspector General, French National Authority for Health
Thomas Müller, Head Of Directorate General 1 - Drugs, Medical Devices, Biotechnology, Federal Ministry of Health Germany
Antonella Cardone, CEO, Cancer Patients Europe
Rimma Berenstein, Deputy Head, Pharmaceuticals Department, G-BA
Mar 210:20
Conference pass
Keynote: Reframing evidence planning for rare diseases in the JCA era - TBC
Keynotes
Session led by: 
Mar 210:40
Conference pass
Keynote: Access by design: Embedding access into core development decisions - TBC
Keynotes
Session led by: 
Mar 212:15
Conference pass
Chair's opening remarks
Track 1 (Market Access)
Paolo Morgese, Vice President, Public Affairs, Europe and Middle East, Alliance for Regenerative Medicine
Track 1
Mar 212:15
Conference pass
Chair's opening remarks
Track 7 (Rare Diseases)
Jorge Arellano, Senior Vice President, Global Head PAVE, Pricing, Access, Value & Evidence, BioMarin
Mar 212:15
Conference pass
Chair's opening remarks
Track 8 (Artificial Intelligence & Data)
Session led by: 
Mar 212:15
Conference pass
Chair's opening remarks
Track 9 (Value & Outcomes)
Caroline van der Meijden, di, iMTA
Mar 212:15
Conference pass
Chair's opening remarks
Track 10 (Sustainable Access & Policy)
Mar 212:15
Conference pass
Chair's opening remarks
Track 6 (Reimbursement)
Adam Gordois, Director, Value Demonstration & HEOR, BioCryst Pharmaceuticals
TRACK 6
Mar 212:15
Conference pass
Chair's opening remarks
Track 2 (HTA)
Track 2
Mar 212:15
Conference pass
Chair's opening remarks
Track 4 (Pre-launch Success)
Track 4
Mar 212:15
Conference pass
Chair's opening remarks
Track 3 (Pricing)
Riad Dirani, Vice President, Global Health Economics, Value and Outcomes, Teva Pharmaceuticals
Track 3
Mar 212:20
Conference pass
Actionable Frameworks for Rapid Market Access Planning
Track 1 (Market Access)
Session led by: 
Mar 212:20
Conference pass
AI will decide who gets access: why drug contracting is becoming pharma’s most strategic capability - TBC
Track 6 (Reimbursement)
Session led by: 
Mar 212:20
Conference pass
Anchoring evidence-based decisions in a volatile policy landscape: strategic considerations for EU HTAR - TBC
Track 5 (Real World Evidence & Data)
Session led by: 
Mar 212:20
Conference pass
CAR-T's Second Act: Reimagining Cell Therapy for the Next Decade
Track 3 (Pricing)
- li>
- How allogeneic and in vivo approaches could overcome today's scalability andmanufacturing constraints
- Expansion beyond hematologic malignancies into solid tumours and autoimmunediseases
- Emerging cell engineering innovations: NK-cell therapies, macrophage therapies,TCR-T, and next-generation CAR designs
- What payers, regulators, and health systems need to prepare for as cell therapiesmove into larger patient populations
- Which technologies are most likely to define the next decade of cell therapyinnovation
Session led by: 
Alexander Grosvenor, Senior Vice President, Managing Director, Precision Value & Health
Richard Macaulay, Senior Vice President, Precision AQ
Mar 212:20
Conference pass
Clearing the fog: A practical guide to EUHTA JCA & expected Country P&R Processes - TBC
Track 9 (Value & Outcomes)
Session led by: 
Mar 212:20
Conference pass
From JSC to HTA: early decisions that shape price and access success
Track 2 (HTA)
Session led by: 
Mar 212:20
Conference pass
Human-in-the-Loop, Generative AI for Joint Clinical Assessment: From PICO Simulations and Living Systematic Literature Reviews to Submission ready JCA Dossiers
Track 8 (Artificial Intelligence & Data)
Session led by: 
Mar 212:20
Conference pass
Most favoured nations, least favoured patients? How US pricing policy could reshape global health equity - TBC
Track 10 (Sustainable Access & Policy)
Session led by: 
Mar 212:20
Conference pass
Quantifying patient flow and costs in rare disease – Benefits for all - TBC
Track 7 (Rare Diseases)
Session led by: 
Mar 212:40
Conference pass
Agility to Enhance Payer Engagement Using AI
Track 8 (Artificial Intelligence & Data)
Mar 212:40
Conference pass
Biosimilar-Enabled Access Repositioning: how to extract more value for patients and health systems
Track 9 (Value & Outcomes)
Delphine Dioudonnat, Executive Director Global Head of Pricing & Biosimilars Market Access, Organon
Mar 212:40
Conference pass
Critical Medicines Act and Recent Policy Changes
Track 10 (Sustainable Access & Policy)
Thomas Müller, Head Of Directorate General 1 - Drugs, Medical Devices, Biotechnology, Federal Ministry of Health Germany
Mar 212:40
Conference pass
Navigating Market Access & Joint Clinical Assessment (JCA)
Track 1 (Market Access)
Lotte Steuten, Deputy CEO, Office of Health Economics
Mar 212:40
Conference pass
Rare disease access under uncertainty
Track 7 (Rare Diseases)
Emanuele Marsili, Global Access Lead, CSL
Mar 212:40
Conference pass
Real World Evidence to Demonstrate Value in Mental Health Treatments
Track 5 (Real World Evidence & Data)
Neeta Tandon, Vice President, Value & Evidence Scientific Engagement, Johnson & Johnson Innovation
Mar 212:40
Conference pass
Results from CAPRICORD - Poland HTA and Patient Involvement - TBC
Track 2 (HTA)
Magdalena Rdzanek, Consultant, AOTMiT
Mar 212:40
Conference pass
Sustainability in reimbursement decisions
Track 6 (Reimbursement)
Sandra Rose, Head of Market Access & Public Affairs, Chiesi
Mar 212:40
Conference pass
The Role of AI in HTA: Perspectives from the HTAi AI & Data Interest Group
Track 2 (HTA)
Rossella Di Bidino, Head of HTA for AI Unit, Graduate School of Health Economics and Management ALTEMS
Mar 212:40
Conference pass
When Geopolitics Sets the Price: Rethinking HTA’s Value Lens to Sustain Pharmaceutical Innovation in Europe
Track 3 (Pricing)
Jose Diaz, Global Health Systems Economics & Value of Innovation, BMS
Mar 213:00
Conference pass
Access starts early: Integrating regulatory and market access to accelerate launch and reduce risk
Track 4 (Pre-launch Success)
Session led by: 
Alberto Rubio, VP, Executive Partner, ProductLife Group
Mar 213:00
Conference pass
Beyond advocacy: a multi-stakeholder panel on patient-informed HTA & economic models - TBC
Track 7 (Rare Diseases)
Session led by: 
Mar 213:00
Conference pass
Designing Reimbursement Frameworks That Match Evolving Payer Thresholds - TBC
Track 6 (Reimbursement)
Session led by: 
Mar 213:00
Conference pass
How AI Is Reshaping JCA Preparation
Track 8 (Artificial Intelligence & Data)
Session led by: 
Daniel Moreira, Co-CEO & Co-Founder, Cellbyte GmbH
Track 8
Mar 213:00
Conference pass
Policy, pricing, and power shifts: how EU, UK, and global policies are reshaping pharma market access - TBC
Track 1 (Market Access)
Session led by: 
Mar 213:20
Conference pass
AI, Avatars, and Access: Revolutionizing Patient Engagement and Real-World Evidence
Track 8 (Artificial Intelligence & Data)
Mar 213:20
Conference pass
Building innovative medicines access capabilities within a historically generics-focused organization
Track 1 (Market Access)
Yulia Voloshchuk, Head of Market Access, Innovative Medicine Europe, Teva
Track 1
Mar 213:20
Conference pass
Mind the Gap: evidence requirements for regulatory, evaluation and adoption - TBC
Track 2 (HTA)
Mar 213:20
Conference pass
Novel types of evidence: can they support reliable HTA decisions?
Track 5 (Real World Evidence & Data)
Steve Sharp, Scientific Advisor, National Institute for Health and Care Excellence
Track 5
Mar 213:20
Conference pass
Reimbursement in China: latest updates
Track 6 (Reimbursement)
Eric Bouteiller, Author & Adjunct Professor, China Europe International Business School (CEIBS)
Track 6
Mar 213:20
Conference pass
Rethinking Pharma Pricing: Budget Pressures, Value Promises, and Gulf Policy Shifts
Track 3 (Pricing)
Mar 213:20
Conference pass
Retrospective Data as a Proof of Concept for Future Healthcare Sustainability - TBC
Track 10 (Sustainable Access & Policy)
Adam PARNABY, Lead, Global Policy & Access, Bristol Myers Squibb
Mar 213:20
Conference pass
Strategic Evidence Generation in Oncology - TBC
Track 9 (Value & Outcomes)
Track 9
Mar 213:20
Conference pass
The missing middle in market access & bridging global strategy with local execution
Track 4 (Pre-launch Success)
Manoj Sood, Commercial Access Director, Independent Market Access Expert
Track 4
Mar 215:10
Conference pass
Advanced Therapeutics: Evidence, Outcomes, and Next-Generation Payment Models
Interactive Panels
Caroline van der Meijden, di, iMTA
Session led by: 
Laurie Kan, Sr. Director, Global Market Access, CSL
Mar 215:10
Conference pass
AI & Digitalization in HTA: Regulation, Transparency and Value
Interactive Panels
Raphael Sonabend-Friend, Associate Director, National Institute for Health and Care Excellence
Marco Marchetti, Co-Chair, HTA Coordination Group & Director, Health Technology Assessment Unit, European Commission & National Agency for Regional Care Services, Italy
Rossella Di Bidino, Head of HTA for AI Unit, Graduate School of Health Economics and Management ALTEMS
Mar 215:10
Conference pass
From Advice to Access: The Role of JSCs in National Pricing and Reimbursement Success
Interactive Panels
Alexander Natz, Secretary General, EUCOPE - European Confederation of Pharmaceutical Entrepreneurs
Moderator: Tina Wang, Director, HTA programme and Strategic Partnership, Center for Innovation in Regulatory Science
Mar 215:10
Conference pass
From silos to systems: HTA & Pharmaceutical companies & The Trump effect in an ever-changing world - TBC
Interactive Panels
Session led by: 
Mar 215:10
Conference pass
Launching Rare Disease Therapies in Europe and Globally: Aligning Evidence, Pricing, and Access from Day One
Interactive Panels
Moderator: Tomaso Piaggio, Head of International Market Access, Pricing & Policy, Alnylam Pharmaceuticals
Jennifer Quinn, Senior Director, Head of Market Access, Europe and International, Jazz Pharmaceuticals
Lorenzo Capretto, Head of HTA Strategy and Pricing, Global Rare Disease, Chiesi Farmaceutici Spa
Stefan Bos, Independent Patient Expert and Speaker, Stefan Bos Consulting
Mar 215:10
Conference pass
Market Access Under Pressure: Practical Solutions to Global Policy Shifts like MFN
Interactive Panels
Moderator: Amy Israel, Senior Advisor, Access to Medicines, Union for International Cancer Control
Marie-Monique de Molliens, Global Market Access Horizon Scanning Senior Director, Sanofi
Anh Bourcet Nguyen, International Director, Government Affairs and Policy, Rare Diseases, AstraZeneca
Mar 215:10
Conference pass
Meaningful patient involvement to improve equity in HTA
Interactive Panels
Valentina Strammiello, Interim Executive Director, European Patients' Forum
Mar 215:10
Conference pass
Pre-launch success for orphan diseases in the JCA era - TBC
Interactive Panels
Session led by: 
Mar 215:10
Conference pass
Title TBC
Interactive Panels
Session led by:
Mar 216:25
Conference pass
Chair's opening remarks
Track 1 (Market Access)
Michael Mueller, Head of Market Access, Western Europe, Sun Pharma
Mar 216:25
Conference pass
Chair's opening remarks
Track 9 (Value & Outcomes)
Peter Pemberton-Ross, Head, HE & HTA Strategy, Biogen
Mar 216:25
Conference pass
Chair's opening remarks
Track 6 (Reimbursement)
Adam Gordois, Director, Value Demonstration & HEOR, BioCryst Pharmaceuticals
TRACK 6
Mar 216:25
Conference pass
Chair's remarks
Track 1 (Market Access)
Michael Mueller, Head of Market Access, Western Europe, Sun Pharma
Mar 216:25
Conference pass
Chair's remarks
Track 7 (Rare Diseases)
Jorge Arellano, Senior Vice President, Global Head PAVE, Pricing, Access, Value & Evidence, BioMarin
Mar 216:25
Conference pass
Chair's remarks
Track 9 (Value & Outcomes)
Peter Pemberton-Ross, Head, HE & HTA Strategy, Biogen
Mar 216:25
Conference pass
Chair's remarks
Track 4 (Pre-launch Success)
Track 4
Mar 216:25
Conference pass
Chair's remarks
Track 3 (Pricing)
Riad Dirani, Vice President, Global Health Economics, Value and Outcomes, Teva Pharmaceuticals
Track 3
Mar 216:25
Conference pass
Mar 216:30
Conference pass
Europe still Under MFN Pressure: Reading Pricing and Reimbursement Signals and Launch Implications
Track 3 (Pricing)
Session led by: 
Track 3
Mar 216:30
Conference pass
Factors impacting GKV rebates for orphan drugs (OD) and the evolution of OD pricing in Germany - TBC
Track 7 (Rare Diseases)
Session led by: 
Mar 216:30
Conference pass
The future of HEOR in HTA: what you need to start doing NOW for improved market access - TBC
Track 1 (Market Access)
Session led by: 
Mar 216:30
Conference pass
The only way is down? Sustaining value through indication expansion - TBC
Track 4 (Pre-launch Success)
Session led by:
Mar 216:30
Conference pass
Trends in HTA and the new launch sequence: market prioritization in a world of changing policies - TBC
Track 2 (HTA)
Session led by: 
Mar 216:50
Conference pass
Deeper payer insights when you need it: How rapid payer research can elevate your market access playbook - TBC
Track 3 (Pricing)
Session led by: 
Mar 217:10
Conference pass
AI in Market Access
Track 8 (Artificial Intelligence & Data)
Mar 217:10
Conference pass
China: risk, threat or opportunity - and for whom?
Track 1 (Market Access)
Neil Grubert, Global Market Access Expert, Independent
Mar 217:10
Conference pass
Germany's new reimbursement policies and the impact on markets
Track 6 (Reimbursement)
Mar 217:10
Conference pass
Health Technology Assessment and Real-World Uptake in Denmark - TBC
Track 2 (HTA)
Birgitte Klindt Poulsen, Chair, Danish Medicines Council
Mar 217:10
Conference pass
How to generate robust RWE to inform HTA/Payer Decision-Making
Track 5 (Real World Evidence & Data)
TRACK 5
Mar 217:10
Conference pass
HTA approval is not the End of Market Access: The Road to Sustainable Access is a Marathon, not a Sprint
Track 4 (Pre-launch Success)
Ana Filipa Alexandre, Senior Director, Pipeline Head for Neuroscience, Teva Pharmaceuticals
Track 4
Mar 217:10
Conference pass
No Green, No Go: How Sustainability is Shifting from a Corporate Responsibility to a Hard Payer Criterion
Track 10 (Sustainable Access & Policy)
Enric Gomez, Director Strategy, Pricing & Analytics, Merck Group
Mar 217:10
Conference pass
No Green, No Go: How Sustainability is Shifting from a Corporate Responsibility to a Hard Payer Criterion
Track 10 (Sustainable Access & Policy)
Enric Gomez, Director Strategy, Pricing & Analytics, Merck Group
Mar 217:10
Conference pass
Policy change impacts on pricing & access of rare disease treatments beyond Europe and US - TBC
Track 7 (Rare Diseases)
Pedro Borga, Global Pricing Director, BioMarin Pharmaceutical Inc.
Mar 217:10
Conference pass
Pricing & reimbursement in an MFN era
Track 3 (Pricing)
Steve Sandor, Vice President, Market Access, Trade and Government Affairs, Paratek Pharmaceuticals , Inc.
Mar 217:10
Conference pass
Title TBC
Track 9 (Value & Outcomes)
Ankita Kaushik, Senior Director, HEOR, Global Value and Access, Gilead Sciences
Track 9
Create your personal agenda –check the favourite icon
Mar 38:55
Conference pass
Mar 39:00
Conference pass
Opening keynote presentation
Keynotes
Brigitte Nolet, Head, Global Access for the Pharmaceuticals Division, Roche
Mar 39:20
Conference pass
Keynote: Beyond the buzzwords: How market access professionals are using AI in practice - TBC
Keynotes
Session led by:
Mar 310:00
Conference pass
Panel: Staying Agile in a Shifting Landscape: Rethinking Global Market Access in the MFN era
Keynotes
How are recent policy developments influencing pricing dynamics and launch sequencing?
Are companies becoming more selective in where and when they launch, and how does this differ for rare & specialty products vs mass-market therapies?
How do you manage pricing risk across interconnected markets without compromising long-term value?
Jorge Arellano, Senior Vice President, Global Head PAVE, Pricing, Access, Value & Evidence, BioMarin
Moderator: Iroda Jurabekova, Executive Director, Global Market Access, Oncology, Boehringer Ingelheim
Mar 312:15
Conference pass
Chair's opening remarks
Track 1 (Market Access)
Keir Woods, Vice President, Global Value Demonstration, Market Access & Pricing (GVAP), Oncology, Merck Group
Mar 312:15
Conference pass
Chair's opening remarks
Track 9 (Value & Outcomes)
Elizabeth Kinter, Vice President, Head of Global Market Access, Avidity BioSciences
Mar 312:15
Conference pass
Chair's opening remarks
Track 4 (Pre-launch Success)
Allister Upton, Value & Access Manager, Novo Nordisk
Track 4
Mar 312:15
Conference pass
Chair's opening remarks
Track 3 (Pricing)
Dilip Patel, SVP Global Pricing and Market Access, Autolus
Mar 312:15
Conference pass
Chair's opening remarks
Track 10 (Sustainable Access & Policy)
Yulia Voloshchuk, Head of Market Access, Innovative Medicine Europe, Teva
Track 10
Mar 312:20
Conference pass
Disruption or evolution? The high-stakes game of drug pricing - TBC
Track 3 (Pricing)
Session led by:
Mar 312:20
Conference pass
EU JCA: methodological challenges, solutions, and early learnings - TBC
Track 1 (Market Access)
Session led by: 
Mar 312:40
Conference pass
A New AI Framework for NICE Evidence Submission
Track 8 (Artificial Intelligence & Data)
Raphael Sonabend-Friend, Associate Director, National Institute for Health and Care Excellence
Mar 312:40
Conference pass
Building resilient healthcare systems in 2027 and beyond
Track 10 (Sustainable Access & Policy)
Mar 312:40
Conference pass
From the Buyer's Side: Why It's Still the Prices, Not the Evidence
Track 5 (Real World Evidence & Data)
Real-world evidence has become central to the market access conversation — but does more evidence actually change what payers cover, or what they pay? Drawing on a career spanning federal health policy, healthcare cost research, and now leading data and analytics for a major US health plan, Niall Brennan offers a candid view from the other side of the table. He'll unpack which real-world evidence payers genuinely use and trust, where it moves coverage decisions and where it doesn't, and why — even in an era of abundant data and AI — the binding constraint on access remains price, not proof. Expect a frank, occasionally contrarian take on the limits of evidence as a substitute for structural reform, and what manufacturers routinely misread about how payers actually decide.
Niall Brennan, Chief Data and Analytics Officer, Blue Cross Blue Shield of New Jersey
Mar 312:40
Conference pass
MFN: Mid to long term implications on market access
Track 1 (Market Access)
Keir Woods, Vice President, Global Value Demonstration, Market Access & Pricing (GVAP), Oncology, Merck Group
Mar 312:40
Conference pass
Reimbursement landscape in the Netherlands
Track 6 (Reimbursement)
Thomas Broekhoff, Program Manager Medicines, hollandbio
Mar 312:40
Conference pass
RWD to identify implementation barriers to build better evidence plans
Track 9 (Value & Outcomes)
Melvin Skip Olson, Founder, Olson Strategies GmbH
Track 9
Mar 312:40
Conference pass
The Impact of EU Pharma Legislation: Defining Unmet Medical Need and Breakthroughs
Track 7 (Rare Diseases)
Thomas Bols, Head of Government Affairs and Patient Advocacy, EMEA & APAC, PTC Therapeutics
Mar 313:00
Conference pass
MFN: why “wait and see” is the most costly strategy - TBC
Track 1 (Market Access)
Session led by: 
Mar 313:20
Conference pass
"The Netherlands in the EU - differences and similarities in access
Track 6 (Reimbursement)
Track 6
Mar 313:20
Conference pass
Comparative pricing in oncology: Germany versus the US – TBC
Track 3 (Pricing)
Joshua Smeltzer, Head of Pricing & Contracting, Market Access Germany, Ipsen Pharma GmbH
Mar 313:20
Conference pass
Developments in access in the US
Track 1 (Market Access)
Mar 313:20
Conference pass
Early Acccess Programs in France
Track 10 (Sustainable Access & Policy)
Frédéric Girard, President, France Biotech
Track 10
Mar 313:20
Conference pass
Enriching QoL Measurement with Lived Experience and Patient Preferences: Can It Improve HTA Decisions and How Should It Be Done Robustly
Track 5 (Real World Evidence & Data)
Vidya Breeveld, founder & CEO, Transmineo
Mar 313:20
Conference pass
Integrated Evidence Generation for launch strategy
Track 4 (Pre-launch Success)
Sandrine Ruiz, Senior Director, Market Access, Pricing & HEOR, Immunocore Ltd
Mar 313:20
Conference pass
The future of AI in market access
Track 8 (Artificial Intelligence & Data)
Marco Rauland, Vice President, Market Access, Strategy, Pricing and Analytics, Merck KGaA
Mar 313:20
Conference pass
Who Counts as Productive? Unpaid Work, Gender Inequality, and Age Bias in HTA
Track 9 (Value & Outcomes)
Karla Hernandez-Villafuerte, Health Economics Research and Innovation Strategy Lead, WifOR
Mar 313:20
Conference pass
Why do we have different reimbursement decisions based on similar evidence?
Track 2 (HTA)
Goedele Van Haasteren, Staff Member, Federal Office of Public Health, Switzerland
Mar 315:10
Conference pass
AI in market access: knowing when it’s the hero (and when it isn’t) - TBC
Interactive Panels
Session led by:
Mar 315:10
Conference pass
Critical capabilities for leadership development: stakeholder management & influence
Interactive Panels
Iroda Jurabekova, Executive Director, Global Market Access, Oncology, Boehringer Ingelheim
Mar 315:10
Conference pass
EU HTA Regulation: Towards Timelier Population Access to Vaccination?
Interactive Panels
A 60-minute moderated roundtable begins with a short presentation of the Vaccines Europe study, followed by a discussion exploring:
· Why do vaccine assessment and access pathways differ from those for other medicinal products?
· Which differences are necessary to reflect the specific nature and value of vaccination, and which may contribute to avoidable delays?
· What should be done now to ensure implementation of the EU HTA Regulation is fit for purpose for vaccines?
· What can vaccine assessors learn from HTA of other medicinal products - and what should be approached differently?
· How should NITAG and HTA processes interact as vaccines move towards JCA scope in 2030?
Anna Vicere, Director, Access Policy & Public Affairs, Vaccines Europe
Lotte Steuten, Deputy CEO, Office of Health Economics
Diane Lastennet, French National Authority for Health
Mar 315:10
Conference pass
Global pricing across the full product lifecycle and impacts of MFN
Interactive Panels
Aveline Godard, Head of Global Pricing & Tendering, Ferring
José Luis Sánchez Chorro, Director, Market Access, Public Affairs, Tenders and Supply, ADVANZ PHARMA
Antti Kourula, Global Head of Market Access, CSL Behring
Mar 315:10
Conference pass
Health System Readiness for Breakout Medical Devices
Interactive Panels
Marco Marchetti, Co-Chair, HTA Coordination Group & Director, Health Technology Assessment Unit, European Commission & National Agency for Regional Care Services, Italy
Teresa Barcina Lacosta, Manager, HTA, MedTech Europe
Mar 315:10
Conference pass
How to Build a Resilient Launch Strategy
Interactive Panels
- Lessons learnt fromsuccessfullaunches
- Use of digital tools and AI to distinguish critical strategic signals from market noise to drive data-led launch strategies
- Generating the right evidence for productlaunches.
jolanda koenders, Policy & Advocacy, takeda
Bruno Cherel, Senior Director, Head of Pricing, Jazz Pharmaceuticals
Mar 315:10
Conference pass
Integrated evidence generation for market access decisions
Interactive Panels
Elizabeth Kinter, Vice President, Head of Global Market Access, Avidity BioSciences
Luca Luigi Polastri, Global Value and Access Head, Nephrology Franchise, Kyowa Kirin
Ana Filipa Alexandre, Senior Director, Pipeline Head for Neuroscience, Teva Pharmaceuticals
Simon McNamara, Senior Director, Real World Evidence, GSK
Niall Brennan, Chief Data and Analytics Officer, Blue Cross Blue Shield of New Jersey
Moderator: Melvin Skip Olson, Founder, Olson Strategies GmbH
Mar 315:10
Conference pass
Lessons learnt from first JCA results, national experiences and comparison of national approaches for pricing & reimbursement decisions
Interactive Panels
Mar 315:10
Conference pass
Securing Fair Pricing and Reimbursement for Value-added Medicines
Interactive Panels
Thomas Grub, Director, Global Pricing and Market Access, Medac GmbH
Klara Marton, International Strategic Business Development Director, Egis Pharmaceuticals Plc
Mar 315:10
Conference pass
The Path to Faster & Sustainable Patient Access in Europe
Interactive Panels
Moderator: Ramiro Gilardino, Associate Professor of Public Health, Buenos Aires School of Public Health
Noem Sain, Director, EU Market Access, UCB Pharma
Alessandro Monaco, General Manager, Oliba Healthcare and Pharma
Mihai Rotaru, Director, Market Access, EFPIA
Sandra Rose, Head of Market Access & Public Affairs, Chiesi
Mar 316:50
Conference pass
Finding Synergies in Diagnostics and Pharma to Secure Sustainable Healthcare Budgets - TBC
Track 10 (Sustainable Access & Policy)
Stefaan Fiers, Chapter Head, External Affairs, Roche
Mar 316:50
Conference pass
Pricing negotiation future in Spain
Track 3 (Pricing)
José Luis Sánchez Chorro, Director, Market Access, Public Affairs, Tenders and Supply, ADVANZ PHARMA
Mar 316:50
Conference pass
Reimbursement and Willingness to Pay - TBC
Track 6 (Reimbursement)
Henriette Burghoorn, Associate Director, Market Access, Gilead Sciences
Track 6
last published: 09/Oct/26 08:55 GMT
Get Involved
Sponsorship & Exhibition Sales
Oliver Hersey-Swan
oliver.hersey-swan@terrapinn.com
Speaking Opportunities
Isla Sutherland
isla.sutherland@terrapinn.com
Marketing Opportunities
Hidy Lee
hidy.lee@terrapinn.com
Created by
Terrapinn is proud to be a member of isla.
Working together to build sustainable events